The General Assembly adjourned sine die on May 8.
Also in Colorado, SB24-168, legislation that requires the Department of Health Care Policy and Financing (HCPF) to provide coverage of continuous glucose monitors (CGMs) to Medicaid patients, passed both houses and will be sent to Gov. Jared Polis (D) to sign into law.
Finally in Colorado, HCPF’s Substance Use Disorder Stakeholder newsletter has been posted online.
For more information, contact NACDS’ Mary Staples at 817-442-1155.
The Family and Social Services Administration (FSSA) Office of Medicaid Policy and Planning (OMPP) published the Monthly Medicaid Financial Report webpage to provide transparency and information about expenditure, enrollment, and funding data of the Indiana Medicaid program.
Also in Indiana, the Health Coverage Programs (IHCP) issued updates approved by the Drug Utilization Board in April.
For more information, contact NACDS’ Mary Staples at 817-442-1155.
The Department of Health and Human Services, Iowa Medicaid posted the following:
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy’s May newsletter is available online.
Also in Kansas, Gov. Laura Kelly (D) reappointed Erick Axcell, PharmD, and Andy Truong, PharmD, to the Board of Pharmacy for an additional four-year term.
For more information, contact NACDS’ Mary Staples at 817-442-1155.
The Department of Health (LDH) requested the Managed Care Organizations (MCOs) start a new project that will span six months, ending September 30, 2024, requiring each MCO to thoroughly review and make corrections to their network reporting to eliminate inaccurate or outdated information.
Also in Louisiana, the May 14 issue of Pharmacy Facts announced that beginning July 1, 2024, Louisiana Medicaid is revising the Single Preferred Drug List (PDL), shifting both brand and generic versions of these drugs to preferred status. With the implementation of the new PDL, prescribing providers are advised to note “brand name necessary” on prescriptions where they want to ensure pharmacies fill their prescriptions with brand name drugs. Absent this notation, individual pharmacists will make the decision on whether to fill the prescription with brand or generic drugs. The new PDL will be posted online.
For more information, contact NACDS’ Mary Staples at 817-442-1155.
MO HealthNet completed the annual review of the pharmacy preferred drug list and utilization management edits.
For more information, contact NACDS’ Mary Staples at 817-442-1155.
The Board of Pharmacy posted the agenda for its upcoming meeting on May 20.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
On May 15, 2024, the New Hampshire Senate Committee on Health considered HB 1365, a bill relative to the substitution of biological products by pharmacies. The bill intends to allow for the substitution by a pharmacist of an interchangeable biological product for another interchangeable biological product. HB 1365 had been previously approved by the House. NACDS will remain engaged on this legislation.
For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.
On May 15, 2024, the State Department of Health held its monthly NYRx, the Medicaid pharmacy benefit program, call for stakeholders in the pharmacy community. The agenda included a wrap up of the state budget, update to over-the-counter COVID-19 testing and pharmacy claims edit.
On May 15, 2024, A9729, a bill related to shared pharmacy services, was approved by the Assembly. Under the bill, “shared pharmacy services” means a system that allows a registered pharmacist or a registered pharmacy, pursuant to a request from another registered pharmacist or pharmacy to process or fill a prescription or order, pursuant to regulations promulgated by the Commissioner of Education. The bill now moves to the Senate where we expect action. NACDS will continue to advocate for the bill’s passage.
For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.